Castle Creek Biosciences develops novel gene therapies to improve lives. The company focuses on cell and gene therapy for patients and families.

Castle Creek Biosciences

Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, 
D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).

Horizon Technology Finance

U.S. Food and Drug Administration

Fidelity Management and Research Company

Valor Equity Partners

Paragon Biosciences

Castle Creek Biosciences, Inc.

The earliest description of what is now known as epidermolysis bullosa (EB) was by Austrian dermatologist Ferdinand Ritter von Hebra in 1870. It’s been 154 years and still there are very limited treatment options and no cures for EB. 

One out of every 20,000 U.S. births, or approximately 200 children yearly, are born with EB. This painful disorder requires a lifetime of daily wound care along with a variety of medical specialists. Those with severe forms of EB usually do not survive past 35 years of age. 

At Castle Creek, we hope our work can one day deliver relief to the people living with EB and their families.

What an incredible four days our team had at the debra of America Care Conference in Atlanta! 

We appreciate everyone who connected with us to share their stories about how epidermolysis bullosa (EB) has impacted their lives. 

Special shout out to our CEO Matthew Gantz for his presentation on our upcoming phase 3 clinical trial. 

#dcc2024 #debracareconference #epidermolysisbullosa

Our CEO, Matthew Gantz, is heading to Atlanta for the debra of America Care Conference, an annual event where people living with epidermolysis bullosa and their families gather for knowledge sharing in a nurturing and supportive environment. 

On July 30, Matt will be sharing an update on Castle Creek’s preparations for a phase 3 clinical trial for a potential treatment for dystrophic epidermolysis bullosa (DEB).  Hope to see you there!

https://lnkd.in/ghMU3QnQ

We’re proud to be a Platinum Sponsor of the upcoming debra of America Care Conference! Our work is fueled by people living with epidermolysis bullosa, who experience a lifetime of challenges that no one should ever have to go through.

Recently, Castle Creek hosted Michelle and Marley, two people living with Epidermolysis Bullosa (EB). 

Michelle shared her story of growing up with EB and how she navigates her day as an adult living with EB.  

Nine-year-old Marley and his mother, Shauna, have just begun their journey into advocacy activities. The room was filled with the warmth of Marley’s smile and his big personality connected with the crowd while Shauna talked to the CCB team. 

These first-hand stories of Michelle and Marley really hit home. Their stories, among the thousands of others, are what fuel our work at Castle Creek. 

We know that a person with EB has to overcome numerous challenges every single day. Simple tasks like bathing and eating can take hours, and that’s just the beginning. 

While there is no cure for EB, we are hopeful that our work can one day help provide relief for those living with this painful condition. 

Learn more about Michelle’s life with EB here: https://lnkd.in/gjFFdYHY

On National Doctors' Day, we celebrate the invaluable contributions doctors  make to healthcare and the critical role they play in healing and saving lives.

Today, we remember the impact of Dr. Martin Luther King, Jr. who called for unity and understanding, to create a world where everyone has the opportunity to flourish. #martinlutherkingjr

Euro

DNSSEC

Google Maps

Content Delivery Network

Mobile Non Scaleable Content

Cloudflare CDN

Google Analytics 4

jsDelivr

Contact Form 7

BootstrapCDN

Chief Legal Officer

Brad Middlekauff

Chief Commercial Officer

Greg Wujek

Vice President Finance

Andrea Kistner

Vice President Human Resources

Edward Russell

AVP Process Sciences

January S. McKee

Senior Vice President, Commercial

Kate Reedy

Associate VP, Clin Ops

Robin Blumenthal

Vice President of Quality

Tim Mitchell

Director of Quality Technology

Clarence Baker

Director, Corporate Communications

Karen Casey

Jeff Hesselberg

Vice President Regulatory & Quality Affairs

Matthew Gantz

Jeff Aronin

Founder and Chairman

Babar Ghias

Chief Operating Officer

Joseph Lillegard

Chief Scientific Officer

Mary Spellman

Chief Medical Officer

Life Science Companies With Fewer Than 100 Employees

Life Science Companies With Fewer Than 50 Employees

Pharmaceutical Companies (Top 10K)

Greater Philadelphia Area Companies With Fewer Than 100 Employees (Top 10K)

Castle Creek Biosciences is focused on developing and commercializing novel, personalized gene therapies for rare skin and connective tissue disorders with high unmet need.

It was founded in 2015 and headquartered in Pennsylvania, United States.

Venture Round - Castle Creek Biosciences

Grant - Castle Creek Biosciences

Debt Financing - Castle Creek Biosciences

Fidelity

Exton

Pennsylvania

United States

North America

Epidermolysis Bullosa Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2034, as per ...

Epidermolysis Bullosa Market to Observe Impressive Growth by (2024-2034), Evaluates DelveInsight | Amryt Pharma ...

Global Drug and Gene Delivery Devices Market Worth $430.25 Billion in 2023 Projected to Reach $956.20 Billion by ...

Dystrophic Epidermolysis Bullosa Management Market ...

Adoptive Cell Therapy Market Is Booming Worldwide 2023 ...

Epidermolysis Bullosa Market Predicted to Grow in United ...

Philly Is Not The Underdog For Life Sciences (Or Football)

Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell and Gene Therapy Platform

A gene therapy for treating dystrophic epidermolysis bullosa (DEB) by using the patient's own genetically modified fibroblasts to express type VII collagen.

A technology platform for developing cell-based, gene therapy candidates targeting monogenic chronic diseases, focusing on skin and connective tissue disorders.

Facility designed for autologous manufacturing of cell product batches, supporting clinical and commercial-scale supply of investigational gene therapies.

A policy outlining conditions under which patients can gain access to investigational products outside of clinical trials, for serious or life-threatening conditions.

news impact assignment basic	general
public peers	general	Aug 31, 2024 2:14 AM	a1dfd56d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	1076e49b
crunchbase profile	general	Nov 25, 2024 10:28 AM	59dbf51b
li profile	general	Aug 31, 2024 2:14 AM	b12cdb11
translate crunchbase fundingrounds	general	Nov 25, 2024 4:25 PM	bd3f685b
peers	general	Aug 31, 2024 2:14 AM	816f372a
news basic	general	Aug 31, 2024 2:14 AM	31b37bf7
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CAST

COM:CASTLECREEKBIO

Castle Creek Biosciences